Skip to main content
Top
Published in: AIDS Research and Therapy 1/2009

Open Access 01-12-2009 | Case report

Adrenal suppression due to an interaction between ritonavir and injected triamcinolone: a case report

Authors: Kathryn Dort, Shetal Padia, Brian Wispelwey, Christopher C Moore

Published in: AIDS Research and Therapy | Issue 1/2009

Login to get access

Abstract

Two HIV-1 infected patients developed signs and symptoms consistent with adrenal suppression after being exposed to intra-articular triamcinolone acetate while also receiving ritonavir as part of their highly active antiretroviral therapy. Laboratory evaluation confirmed secondary adrenal suppression in both cases. Both patients recovered without the need for chronic replacement steroids. Adrenal suppression has been described as an adverse outcome in patients treated with fluticasone and concomitant ritonavir. In the reported cases, the adrenal suppression likely developed as a result of increased systemic concentrations of triamcinolone due to an inhibition of cytochrome p450 3A4 metabolism. Practitioners of HIV medicine should be aware of the potential negative interaction of injected triamcinolone and ritonavir.
Appendix
Available only for authorised users
Literature
1.
go back to reference St Germain RM, Yigit S, Wells L, Girotto JE, Salazar JC: Cushing syndrome and severe adrenal suppression caused by fluticasone and protease inhibitor combination in an HIV-infected adolescent. AIDS Patient Care STDS. 2007, 21: 373-7. 10.1089/apc.2006.0117CrossRefPubMed St Germain RM, Yigit S, Wells L, Girotto JE, Salazar JC: Cushing syndrome and severe adrenal suppression caused by fluticasone and protease inhibitor combination in an HIV-infected adolescent. AIDS Patient Care STDS. 2007, 21: 373-7. 10.1089/apc.2006.0117CrossRefPubMed
2.
go back to reference Foisy MM, Yakiwchuk EM, Chiu I, Singh AE: Adrenal suppression and Cushing's syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature. HIV Med. 2008, 9: 389-96. 10.1111/j.1468-1293.2008.00579.xCrossRefPubMed Foisy MM, Yakiwchuk EM, Chiu I, Singh AE: Adrenal suppression and Cushing's syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature. HIV Med. 2008, 9: 389-96. 10.1111/j.1468-1293.2008.00579.xCrossRefPubMed
3.
go back to reference Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR: Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals. J Acquir Immune Defic Syndr. 2008, 48: 561-6. 10.1097/QAI.0b013e31817bebebPubMedCentralCrossRefPubMed Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR: Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals. J Acquir Immune Defic Syndr. 2008, 48: 561-6. 10.1097/QAI.0b013e31817bebebPubMedCentralCrossRefPubMed
4.
go back to reference Gondwe JS, Davidson JE, Deeley S, Sills J, Cleary AG: Secondary Cushing's syndrome in children with juvenile idiopathic arthritis following intra-articular triamcinolone acetonide administration. Rheumatology (Oxford). 2005, 44: 1457-8. 10.1093/rheumatology/kei154CrossRef Gondwe JS, Davidson JE, Deeley S, Sills J, Cleary AG: Secondary Cushing's syndrome in children with juvenile idiopathic arthritis following intra-articular triamcinolone acetonide administration. Rheumatology (Oxford). 2005, 44: 1457-8. 10.1093/rheumatology/kei154CrossRef
5.
go back to reference Kumar S, Singh RJ, Reed AM, Lteif AN: Cushing's syndrome after intra-articular and intradermal administration of triamcinolone acetonide in three pediatric patients. Pediatrics. 2004, 113: 1820-4. 10.1542/peds.113.6.1820CrossRefPubMed Kumar S, Singh RJ, Reed AM, Lteif AN: Cushing's syndrome after intra-articular and intradermal administration of triamcinolone acetonide in three pediatric patients. Pediatrics. 2004, 113: 1820-4. 10.1542/peds.113.6.1820CrossRefPubMed
6.
go back to reference Horani MH, Silverberg AB: Secondary Cushing's syndrome after a single epidural injection of a corticosteroid. Endocr Pract. 2005, 11: 408-10.CrossRefPubMed Horani MH, Silverberg AB: Secondary Cushing's syndrome after a single epidural injection of a corticosteroid. Endocr Pract. 2005, 11: 408-10.CrossRefPubMed
7.
go back to reference Boyle BA, Elion RA, Moyle GJ, Cohen CJ: Considerations in selecting protease inhibitor therapy. AIDS Rev. 2004, 6: 218-25.PubMed Boyle BA, Elion RA, Moyle GJ, Cohen CJ: Considerations in selecting protease inhibitor therapy. AIDS Rev. 2004, 6: 218-25.PubMed
8.
go back to reference Gallant JE: Protease-inhibitor boosting in the treatment-experienced patient. AIDS Rev. 2004, 6: 226-33.PubMed Gallant JE: Protease-inhibitor boosting in the treatment-experienced patient. AIDS Rev. 2004, 6: 226-33.PubMed
9.
go back to reference Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J: Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers. J Acquir Immune Defic Syndr. 2005, 40: 573-80. 10.1097/01.qai.0000187444.38461.70CrossRefPubMed Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J: Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers. J Acquir Immune Defic Syndr. 2005, 40: 573-80. 10.1097/01.qai.0000187444.38461.70CrossRefPubMed
11.
go back to reference Hopkins RL, Leinung MC: Exogenous Cushing's syndrome and glucocorticoid withdrawal. Endocrinol Metab Clin North Am. 2005, 34: 371-84. 10.1016/j.ecl.2005.01.013CrossRefPubMed Hopkins RL, Leinung MC: Exogenous Cushing's syndrome and glucocorticoid withdrawal. Endocrinol Metab Clin North Am. 2005, 34: 371-84. 10.1016/j.ecl.2005.01.013CrossRefPubMed
12.
go back to reference Derendorf H, Mollmann H, Gruner A, Haack D, Gyselby G: Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intra-articular administration. Clin Pharmacol Ther. 1986, 39: 313-7.CrossRefPubMed Derendorf H, Mollmann H, Gruner A, Haack D, Gyselby G: Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intra-articular administration. Clin Pharmacol Ther. 1986, 39: 313-7.CrossRefPubMed
13.
go back to reference Ramanathan R, Pau AK, Busse KH, Zemskova M, Nieman L, Kwan R, Hammer JH, Mican JM, Maldarelli F: Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir. Clin Infect Dis. 2008, 47: e97-9. 10.1086/593314PubMedCentralCrossRefPubMed Ramanathan R, Pau AK, Busse KH, Zemskova M, Nieman L, Kwan R, Hammer JH, Mican JM, Maldarelli F: Iatrogenic Cushing syndrome after epidural triamcinolone injections in an HIV type 1-infected patient receiving therapy with ritonavir-lopinavir. Clin Infect Dis. 2008, 47: e97-9. 10.1086/593314PubMedCentralCrossRefPubMed
14.
go back to reference Yombi JC, Maiter D, Belkhir L, Nzeusseu A, Vandercam B: Iatrogenic Cushing's syndrome and secondary adrenal insufficiency after a single intra-articular administration of triamcinolone acetonide in HIV-infected patients treated with ritonavir. Clin Rheumatol. 2008, 27 (Suppl 2): S79-82. 10.1007/s10067-008-1022-xCrossRefPubMed Yombi JC, Maiter D, Belkhir L, Nzeusseu A, Vandercam B: Iatrogenic Cushing's syndrome and secondary adrenal insufficiency after a single intra-articular administration of triamcinolone acetonide in HIV-infected patients treated with ritonavir. Clin Rheumatol. 2008, 27 (Suppl 2): S79-82. 10.1007/s10067-008-1022-xCrossRefPubMed
Metadata
Title
Adrenal suppression due to an interaction between ritonavir and injected triamcinolone: a case report
Authors
Kathryn Dort
Shetal Padia
Brian Wispelwey
Christopher C Moore
Publication date
01-12-2009
Publisher
BioMed Central
Published in
AIDS Research and Therapy / Issue 1/2009
Electronic ISSN: 1742-6405
DOI
https://doi.org/10.1186/1742-6405-6-10

Other articles of this Issue 1/2009

AIDS Research and Therapy 1/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine